Meeting
2013 ASCO Annual Meeting
Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study.
Authors
Richard Greil
Universitätsklinikum der PMU, Salzburg, Austria
Richard Greil , Roger Von Moos , Jaafar Bennouna , Pia J. Osterlund , Thierry André , Eric Van Cutsem , Stefan Kubicka , Dirk Arnold , Jose Maria Vieitez de Prado , Olivier Bouche , Vicente Alonso , Christophe Borg , Christoph Schlichting , Claus-Christoph Steffens , Stuart Osborne , Daniel Waterkamp , Martina Makrutzki , Javier Sastre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00700102
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3604)
DOI
10.1200/jco.2013.31.15_suppl.3604
Abstract #
3604
Poster Bd #
9F
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.
First Author: Stefan Kubicka
Poster
2021 Gastrointestinal Cancers Symposium
Is antiangiogenic therapy necessary for patients with metastatic colorectal cancer (mCRC) and mutation in the BRAF gene? Results of the systematic review and meta-analysis.
First Author: Mikhail Fedyanin
Poster
2016 ASCO Annual Meeting
Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance).
First Author: Andrew B. Nixon
Poster
2015 Gastrointestinal Cancers Symposium
Exploratory analysis of a prognosis predictive formula for metastatic colorectal cancer treated with chemotherapy.
First Author: Mamoru Tanaka